Azitra (NYSEAMERICAN:AZTR) Issues Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Azitra (NYSEAMERICAN:AZTR) released its quarterly earnings results on Tuesday. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.31, Zacks reports.

Azitra Stock Performance

Shares of NYSEAMERICAN:AZTR traded down $0.04 during trading on Thursday, hitting $0.45. The company’s stock had a trading volume of 188,011 shares, compared to its average volume of 888,446. Azitra has a fifty-two week low of $0.43 and a fifty-two week high of $68.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.77 and a current ratio of 0.77.

About Azitra

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.